Table 1.
The relationship between the overall survival rate and FSCN family.
| FSCN1 |
FSCN2 |
FSCN3 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer type | Endpoint | Case | Cohort | p-value | Log-rank test statistics | Risk | p-value | Log-rank test statistics | Risk | p-value | Log-rank test statistics | Risk |
| Acute Myeloid Leukemia (LAML) | Overall survival | 161 | TCGA | 0.8556 | 0.03311 | High | 0.7654 | 0.08902 | High | 0.9216 | 0.009675 | Low |
| Adrenocortical Cancer (ACC) | Overall survival | 79 | TCGA | 0.000008006 | 19.94 | High | 0.01814 | 5.582 | High | 0.8998 | 0.01586 | High |
| Bile Duct Cancer (CHOL) | Overall survival | 45 | TCGA | 0.8954 | 0.01729 | High | 0.01858 | 5.541 | Low | 0.4946 | 0.4665 | High |
| Bladder Cancer (BLCA) | Overall survival | 425 | TCGA | 0.08484 | 2.97 | High | 0.7967 | 0.06637 | Low | 0.7141 | 0.1342 | Low |
| Breast Cancer (BRCA) | Overall survival | 1214 | TCGA | 0.7528 | 0.09919 | Low | 0.0003311 | 12.89 | Low | 0.6949 | 0.1538 | High |
| Cervical Cancer (CESC) | Overall survival | 307 | TCGA | 0.09286 | 2.824 | High | 0.7861 | 0.07362 | High | 0.234 | 1.416 | High |
| Colon and Rectal Cancer (COADREAD) | Overall survival | 250 | TCGA | 0.07314 | 3.211 | High | 0.0426 | 4.111 | High | 0.5161 | 0.4217 | High |
| Colon Cancer (COAD) | Overall survival | 326 | TCGA | 0.0301 | 4.704 | High | 0.03691 | 4.354 | High | 0.178 | 1.814 | High |
| Endometrioid Cancer (UCEC) | Overall survival | 189 | TCGA | 0.2443 | 1.356 | High | 0.1384 | 2.196 | High | 0.5209 | 0.4121 | High |
| Esophageal Cancer (ESCA) | Overall survival | 196 | TCGA | 0.8227 | 0.0502 | High | 0.5332 | 0.3883 | High | 0.8606 | 0.03085 | Low |
| Glioblastoma (GBM) | Overall survival | 166 | TCGA | 0.9675 | 0.001656 | Low | 0.2284 | 1.451 | High | 0.9988 | 0.000002288 | High |
| Head and Neck Cancer (HNSC) | Overall survival | 565 | TCGA | 0.0313 | 4.637 | High | 0.8648 | 0.02898 | High | 0.7678 | 0.08714 | High |
| Kidney Chromophobe (KICH) | Overall survival | 89 | TCGA | 0.3003 | 1.073 | Low | 0.5292 | 0.3959 | Low | 0.6487 | 0.2075 | Low |
| Kidney Clear Cell Carcinoma (KIRC) | Overall survival | 606 | TCGA | 0.03181 | 4.609 | High | 0.006612 | 7.375 | High | 0.0253 | 5.003 | High |
| Kidney Papillary Cell Carcinoma (KIRP) | Overall survival | 322 | TCGA | 0.3914 | 0.7346 | Low | 0.4047 | 0.6944 | Low | 0.7855 | 0.0741 | Low |
| Large B-cell Lymphoma (DLBC) | Overall survival | 48 | TCGA | 0.3779 | 0.7775 | Low | 0.3381 | 0.9175 | High | 0.6996 | 0.1489 | Low |
| Liver Cancer (LIHC) | Overall survival | 422 | TCGA | 0.1047 | 2.633 | High | 0.4772 | 0.5053 | High | 0.3422 | 0.902 | High |
| Lower Grade Glioma (LGG) | Overall survival | 528 | TCGA | 0.07948 | 3.075 | High | 0.001565 | 10 | High | 0.9924 | 0.00008962 | Low |
| lower grade glioma and glioblastoma (GBMLGG) | Overall survival | 694 | TCGA | 0.00E+00 | 42.8 | High | 0.00E+00 | 39.32 | High | 0.00E+00 | 35.64 | High |
| Lung Adenocarcinoma (LUAD) | Overall survival | 567 | TCGA | 0.004941 | 7.901 | High | 0.3183 | 0.9959 | Low | 0.003331 | 8.617 | Low |
| Lung Cancer (LUNG) | Overall survival | 1062 | TCGA | 0.005903 | 7.58 | High | 0.7667 | 0.08801 | High | 0.1034 | 2.653 | Low |
| Lung Squamous Cell Carcinoma (LUSC) | Overall survival | 495 | TCGA | 0.9843 | 0.0003853 | Low | 0.2124 | 1.555 | High | 0.9689 | 0.001519 | High |
| Melanoma (SKCM) | Overall survival | 457 | TCGA | 0.2627 | 1.255 | Low | 0.002391 | 9.222 | Low | 0.0715 | 3.248 | High |
| Mesothelioma (MESO) | Overall survival | 86 | TCGA | 0.00007813 | 15.6 | High | 0.4645 | 0.535 | High | 0.699 | 0.1496 | Low |
| Ocular melanomas (UVM) | Overall survival | 80 | TCGA | 0.9311 | 0.007473 | High | 0.3393 | 0.913 | High | 0.5495 | 0.3582 | Low |
| Ovarian Cancer (OV) | Overall survival | 307 | TCGA | 0.2355 | 1.408 | High | 0.1991 | 1.649 | High | 0.8905 | 0.01894 | Low |
| Pancreatic Cancer (PAAD) | Overall survival | 183 | TCGA | 0.06491 | 3.407 | High | 0.06578 | 3.385 | Low | 0.01428 | 6.004 | Low |
| Pheochromocytoma & Paraganglioma (PCPG) | Overall survival | 187 | TCGA | 0.07147 | 3.249 | Low | 0.01778 | 5.618 | Low | 0.5271 | 0.4 | Low |
| Prostate Cancer (PRAD) | Overall survival | 550 | TCGA | 0.9567 | 0.00295 | High | 0.3856 | 0.7528 | Low | 0.4765 | 0.5068 | high |
| Rectal Cancer (READ) | Overall survival | 58 | TCGA | 0.8169 | 0.05361 | Low | 0.2931 | 1.105 | High | 0.3266 | 0.9625 | Low |
| Sarcoma (SARC) | Overall survival | 265 | TCGA | 0.01546 | 5.864 | High | 0.08581 | 2.951 | Low | 0.01136 | 6.408 | Low |
| Stomach Cancer (STAD) | Overall survival | 443 | TCGA | 0.338 | 0.9179 | High | 0.7561 | 0.0965 | High | 0.8238 | 0.04955 | high |
| Testicular Cancer (TGCT) | Overall survival | 139 | TCGA | 0.5686 | 0.3249 | Low | 0.4313 | 0.6193 | High | 0.0644 | 3.42 | Low |
| Thymoma (THYM) | Overall survival | 121 | TCGA | 0.09627 | 2.766 | High | 0.4999 | 0.4551 | High | 0.3964 | 0.7191 | Low |
| Thyroid Cancer (THCA) | Overall survival | 572 | TCGA | 0.1477 | 2.096 | High | 0.2651 | 1.242 | High | 0.7129 | 0.1354 | high |
| Uterine Carcinosarcoma (UCS) | Overall survival | 57 | TCGA | 0.2991 | 1.078 | Low | 0.474 | 0.5126 | Low | 0.346 | 0.8879 | Low |
The correlation between the Fascin family and patients with cancer is listed based on “The Cancer Genome Atlas Program” generated from the XENA websites.